Rest Ez Inc. (RTEZ) intrinsic value & 10-year financials

Rest Ez Inc. (RTEZ) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 6 fiscal years revenue shrank 63.8% a year to $0, with an average return on invested capital of -141.2%.

Graham intrinsic value
—
Share price (Oct 17, 2026)
$70.00
Market cap
$1.9B
Revenue (FY2025)
$0
Revenue growth (6-yr CAGR)
-63.8%
ROIC (10-yr avg)
-141.2%
Free cash flow (FY2025)
—

RTEZ 10-year financial history

Fiscal year Revenue Net income EPS (diluted) Free cash flow Operating margin ROIC
FY2025 $0 -$7.9K $0.00 — — 43.3%
FY2024 $5.0K -$19.4K $0.00 — -387.7% 18.7%
FY2023 $0 -$428.7K -$0.02 — — -1082.8%
FY2022 $519.4K $172.0K $0.01 — 43.1% 154.0%
FY2021 $105.0K -$23.2K $0.00 — -12.0% 160.8%
FY2020 — — — — — —

Source: annual 10-K filings on SEC EDGAR. Figures in USD.

Executive summary

REST EZ Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.

REST EZ Inc. returns on capital have been average, hovering around 10.9% ROIC over the decade.

REST EZ Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.

Benjamin Graham lens

Under Benjamin Graham's formula using SEC EDGAR fundamentals, REST EZ Inc. is modeled at -63.8% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-1.03 per share.

RTEZ stock: frequently asked questions

What is the intrinsic value of Rest Ez Inc. (RTEZ) stock?

Graham's formula only works with positive earnings. Rest Ez Inc. reported diluted EPS of $0.00 in fiscal 2025, so no Graham value is shown. The 10-year table shows revenue and cash-flow trends instead.

What is RTEZ's return on invested capital?

Average ROIC over the last 6 fiscal years was -141.2%, and average return on equity was -120.7%. Sustained ROIC above about 15% usually points to a durable competitive advantage.

Where does this RTEZ data come from?

From Rest Ez Inc.'s annual 10-K filings on SEC EDGAR, most recently filed Feb 10, 2026. Prices are end-of-day snapshots; valuations are formula outputs, not investment advice.

Similar pharmaceutical preparations stocks